Our findings had clear implications for SLAMF1 and TRAF3IP3 as biomarkers for predicting the prognosis of HBV-related HCC patients and provide new research directions and diagnosis and treatment options for HBV-related HCC. The gene discussed is SLAMF1; the disease is hepatocellular carcinoma.